Crossject (ALCJ) - Total Liabilities
Based on the latest financial reports, Crossject (ALCJ) has total liabilities worth €35.30 Million EUR (≈ $41.27 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Crossject - Total Liabilities Trend (2010–2025)
This chart illustrates how Crossject's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Crossject's working capital to evaluate short-term liquidity relative to the company's equity base.
Crossject Competitors by Total Liabilities
The table below lists competitors of Crossject ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mdevice
KQ:226590
|
Korea | ₩68.93 Billion |
|
Kino Polska TV SA
WAR:KPL
|
Poland | zł114.56 Million |
|
Thai Optical Group Public Company Limited
BK:TOG
|
Thailand | ฿2.15 Billion |
|
Grupo Ortiz Properties Socimi
MC:YGOP
|
Spain | €101.27 Million |
|
Luda Technology Group Limited
NYSE MKT:LUD
|
USA | $26.24 Million |
|
Piscines Desjoyaux SA
PA:ALPDX
|
France | €58.08 Million |
|
District Metals Corp
V:DMX
|
Canada | CA$493.27K |
|
Lyko Group A
ST:LYKO-A
|
Sweden | Skr2.05 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down Crossject's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALCJ company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -7.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Crossject's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Crossject (2010–2025)
The table below shows the annual total liabilities of Crossject from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €35.30 Million ≈ $41.27 Million |
+3.10% |
| 2024-12-31 | €34.24 Million ≈ $40.03 Million |
+0.97% |
| 2023-12-31 | €33.91 Million ≈ $39.64 Million |
+12.38% |
| 2022-12-31 | €30.17 Million ≈ $35.28 Million |
-18.46% |
| 2021-12-31 | €37.01 Million ≈ $43.26 Million |
+6.58% |
| 2020-12-31 | €34.72 Million ≈ $40.59 Million |
+61.63% |
| 2019-12-31 | €21.48 Million ≈ $25.11 Million |
+16.08% |
| 2018-12-31 | €18.50 Million ≈ $21.63 Million |
+59.11% |
| 2017-12-31 | €11.63 Million ≈ $13.60 Million |
+46.01% |
| 2016-12-31 | €7.97 Million ≈ $9.31 Million |
+56.75% |
| 2015-12-31 | €5.08 Million ≈ $5.94 Million |
+30.64% |
| 2014-12-31 | €3.89 Million ≈ $4.55 Million |
-17.28% |
| 2013-12-31 | €4.70 Million ≈ $5.50 Million |
+4.54% |
| 2012-12-31 | €4.50 Million ≈ $5.26 Million |
-10.71% |
| 2011-12-31 | €5.04 Million ≈ $5.89 Million |
-54.46% |
| 2010-12-31 | €11.06 Million ≈ $12.93 Million |
-- |
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more